jcp conference-coverage

Conference Coverage

Third-Line Chemotherapy With or Without Trastuzumab-Based Therapy for Metastatic Breast Cancer

12/06/2021

Janelle Bradley

The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.

The inclusion of...

12/06/2021

Journal of Clinical Pathways

Conference Coverage

Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases

12/06/2021

Janelle Bradley

Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.

Palbociclib plus letrozole is...

12/06/2021

Journal of Clinical Pathways

Conference Coverage

Treatment Preferences for Relapsed/Refractory MM in Later Lines of Therapy

10/07/2021

Marta Rybczynski

Findings from a recent study revealed that oncologists place higher relative importance on OS, PFS, and ORR, and prefer a decreased risk of grade 3/4 keratopathy and thrombocytopenia when choosing later line therapies in relapsed/refractory...

Findings from a recent study...

10/07/2021

Journal of Clinical Pathways

Conference Coverage

HRQOL With Nivolumab Plus Chemo vs Chemo Alone Among Patients With Gastrointestinal Cancers

10/04/2021

Marta Rybczynski

Compared with chemotherapy alone, nivolumab added to chemotherapy maintained health-related quality of life with a decreased risk of symptom deterioration in patients with previously untreated advanced or metastatic gastric...

Compared with chemotherapy...

10/04/2021

Journal of Clinical Pathways

Conference Coverage

Trends in Total and Out-of-Pocket Cost Among Privately Insured Patients With Cancer

10/04/2021

Marta Rybczynski

The rise in cancer treatment costs in combination with the increase of cost-sharing have financially burdened privately insured, nonelderly patients with cancer.

The rise in cancer treatment...

10/04/2021

Journal of Clinical Pathways

Conference Coverage

10/04/2021

Marta Rybczynski

According to a study presented at the 2021 ASCO Quality Care Symposium, cost-related prescription nonadherence is associated with higher health care cost responsibility in cancer survivors, especially for those living in rural compared to...

According to a study presented...

10/04/2021

Journal of Clinical Pathways

Conference Coverage

Changes in PROs Can Predict Treatment Response and Survival in Metastatic Gastrointestinal Cancer

10/04/2021

Marta Rybczynski

Results from a study presented at the 2021 ASCO Quality Care Symposium showed that 1-month changes in patient-reported outcomes predicted treatment responses and survival outcomes among patients with metastatic GI cancer.

Results from a study presented...

10/04/2021

Journal of Clinical Pathways

Conference Coverage

Platform Identifies Discrepancies Between Practice Guidelines and Real-World Practice Patterns in MM

07/22/2021

An analysis of patient data using an online patient portal suggests a disparity exists between practice recommendations and real-world practice patterns for patients with MM.

An analysis of patient data...

07/22/2021

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness of Perioperative Chemotherapy vs Adjuvant Chemoradiation for Gastric Cancer

07/20/2021

A recent study comparing perioperative chemotherapy with adjuvant chemoradiotherapy among patients with gastric cancer suggests that perioperative chemotherapy may be more cost-effective.

A recent study comparing...

07/20/2021

Journal of Clinical Pathways

Conference Coverage

Cardiac Risk Factors and Adverse Events Among Patients With CLL Treated in Real-World Setting

07/15/2021

Real-world study findings reveal higher cardiovascular adverse event rates among patients with CLL receiving ibrutinib monotherapy, when compared to those receiving intensive therapy.

Real-world study findings reveal...

07/15/2021

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products